Cancer cells do not act alone. Treatment response is shaped by the surrounding tumor microenvironment, including stromal cells, immune cells, and the extracellular matrix, and this premise framed a recent Bio X Cell-hosted webinar presented by Dr. Nao Nishida-Aoki. Now an associate professor at Waseda University, Dr. Nishida-Aoki presented work from her postdoctoral training in the Gujral Lab at Fred Hutchinson Cancer Center, detailing a 3D tissue screening platform developed to capture tumor microenvironment biology that conventional cell culture does not.
The Limits of Screening Cancer Cells in Isolation
Two-dimensional cell culture has supported cancer biology for more than 50 years and remains effective for genomic and molecular studies. It does not, however, capture tissue context: the interactions between cancer cells, stromal cells, immune cells, and the extracellular matrix that determine how a tumor behaves. Patient tumors and animal models preserve this complexity but are not practical for screening at scale.
To address this gap, the Gujral Lab developed organotypic tissue slice culture, or 3D microtumors: thin sections of tumor tissue that retain native cell composition and architecture while remaining compatible with drug screening workflows.
Comparing Drug Response in 3D and 2D
The study's central experiment compared drug response directly across both systems. The team tested approximately 30 kinase inhibitors in 3D microtumors and in 2D monolayers derived from the same mouse breast and pancreatic tumor lines, then applied a machine learning approach to predict responses to nearly 400 additional compounds.
The 3D microtumors identified substantially more effective drugs than the 2D cultures did. According to Dr. Nishida-Aoki, conventional 2D screening alone would have missed a meaningful proportion of these compounds. This finding is central to the study: tissue context does not simply add nuance to drug response data, it can determine whether a compound appears effective at all.
Mechanism: Doramapimod and the DDR1/2-MAPK12-GLI1 Axis
Doramapimod, a pan-p38 MAPK inhibitor, emerged as a clear example of tissue-context-dependent activity. The compound reduced viability in 3D microtumors and suppressed tumor growth in mouse models, but had no measurable effect on the same cancer cells grown as a 2D monolayer. This indicates that doramapimod does not act directly on cancer cells but acts on tumor microenvironment.
The mechanism was traced in part to an off-target effect. In addition to its known target p38/MAPK12, doramapimod inhibits DDR1 and DDR2, collagen receptors expressed on cancer-associated fibroblasts (CAFs). This inhibition suppresses the DDR1/2–MAPK12–GLI1 signaling axis and reduce CAF-driven extracellular matrix production. This remodeling increased tumor sensitivity to standard therapy, with enhanced gemcitabine response observed in pancreatic models and enhanced anti-PD-L1 checkpoint blockade response in breast cancer models. The enhanced gemcitabine response was further confirmed in human pancreatic ductal adenocarcinoma tissue slices.
The anti-PD-L1 antibody used in the combination studies was Bio X Cell's InVivoPlus anti-mouse PD-L1, credited directly in the presentation:
"The anti-PD-L1 antibody used in this study was InVivoPlus anti-mouse PD-L1 provided by Bio X Cell, and we are thankful to them for making this reliable agent for our studies."
Translational Application and Current Research
Dr. Nishida-Aoki closed this portion of her talk by describing a translational application: using patient tumor tissue slices, prepared after surgical resection, to test multiple drugs or drug combinations directly in support of personalized treatment selection. She then outlined her current research, which extends the same tissue-context framework to cancer-derived extracellular vesicles and their role in shaping pre-metastatic niches in distant organs.
Full Presentation and Publication
This recap summarizes the core findings presented in Dr. Nishida-Aoki's talk. For complete methodology, statistical detail, and her extended discussion of extracellular vesicle research, the full webinar recording is available on demand. The published study appears in Cell Reports Medicine (Nishida-Aoki et al., 2025; DOI: 10.1016/j.xcrm.2025.102357).